Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
My View
Tags:

AHP diet drug settlement

  • News

Executive Summary

Preliminary approval is granted to the $3.75 bil. Redux diet drug settlement, American Home Products announced Nov. 23. Beginning Dec. 1, a 120-day public notice period will commence during which "a variety of media will be used to reach the settlement class members." The class-action settlement is open to any individuals who took Redux (dexfenfluramine) or Pondimin (fenfluramine) regardless of whether or not they have lawsuits pending ("The Pink Sheet" Oct. 11, p. 28). The AmericanWarner merger agreement includes an escape clause for Warner-Lambert if the Redux liability is not resolved

Table

View full table

Tags:
Latest Headlines

ICER Debuts Clinical Trial Diversity Assessment Framework

US FDA Wants Advice About Advisory Committees: Try Having Some?

Shionogi: Other Countries Must Follow UK’s Lead On Antimicrobial Incentives

Industry Calls For Caution Over EMA Supply Chain Recommendations

See All
UsernamePublicRestriction

Register

PS035225

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By